Loading stock data…
Tonix Pharmaceuticals Holding Corp (TNXP)
$13.16+0.02 (+0.15%)
Market ClosedLast close Sep 8
Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Tonix Pharmaceuticals Holding Corp. in the Healthcare sector is trading at $13.16 with a market capitalization of $178M. Wall Street consensus targets $42.40 (5 analysts), implying a +222.2% move over the next 12 months. The stock is currently near its 52-week low of $9.40, remaining 6.6% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: MACD remains below its signal line. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +222.2% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $6.88M↑ | $5.39M↑ | $3.29M↑ | $2.00M↓ | $2.43M |
| Gross Profit | $5.30M↑ | $4.33M↑ | $1.92M↑ | -$1.27M↓ | $1.49M |
| Operating Income | -$41.54M↑ | -$48.22M↓ | -$32.09M↓ | -$27.26M↓ | -$15.13M |
| Net Income | -$40.19M↑ | -$46.91M↓ | -$32.01M↓ | -$28.27M↓ | -$16.83M |
Peer Comparison
JNJUNHPFE
Fundamentals
Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$177.74M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-64.89%
Volume
Today's trading volume
362,128
Recent News
Tonix Pharmaceuticals Highlights TONMYA Sales Surge, Lyme and Depression Pipeline
Tonix Pharmaceuticals (NASDAQ:TNXP) is focusing its near-term strategy on the commercial launch of TONMYA for fibromyalgia while advancing development programs in Lyme disease prevention and major depressive disorder, Chief Executive Officer Seth Lederman said during a Canaccord Genuity conference p
Tonix Pharmaceuticals (TNXP) Q2 2026 Earnings Call Transcript
TONMYA sales hit $11 million in its second quarter on market.
Tonix Pharmaceuticals Holding Corp (TNXP) (Q2 2026) Earnings Call Highlights: TONMYA Surges ...
Tonix Pharmaceuticals reports record TONMYA sales of $11 million in Q2 2026, with prescriptions doubling quarter-over-quarter and market access expanding to 136 million covered lives.
Tonix Pharmaceuticals Q2 Earnings Call Highlights
Tonix Pharmaceuticals (NASDAQ:TNXP) reported second-quarter 2026 net product revenue of approximately $13.5 million, led by $11 million in sales of fibromyalgia treatment Tonmya. The company said Tonmya sales rose 197% from the first quarter, its second full quarter of commercial sales following the
Tonix Expands TONMYA Medicare Coverage with New Payer Agreement (TNXP)
Medicare Deal Broadens Access to TONMYATonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) has signed a new managed Medicare payer agreement for its fibromyalgia treatment TONMYA® (cyclobenzaprine HCl sublingual tablets), extending the drug’s potential coverage to around 9 million additional Medicare beneficiaries.